We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · September 01, 2021

Adalimumab With Surgery in Moderate to Severe Hidradenitis Suppurativa

JAMA Surgery


Additional Info

JAMA Surgery
Efficacy and Safety of Adalimumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa: The SHARPS Randomized Clinical Trial
JAMA Surg 2021 Aug 18;[EPub Ahead of Print], FG Bechara, M Podda, EP Prens, B Horváth, EJ Giamarellos-Bourboulis, A Alavi, JC Szepietowski, J Kirby, Z Geng, C Jean, GBE Jemec, CC Zouboulis

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading